Status:
UNKNOWN
Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals
Lead Sponsor:
Ningbo No. 1 Hospital
Collaborating Sponsors:
The First Afliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Conditions:
Non-Alcoholic Fatty Liver Disease
Hyperuricemia
Eligibility:
All Genders
18-80 years
Brief Summary
Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders. A growing body of evidence, comprising a great deal of cross...
Detailed Description
A cohort study was conducted to evaluate the relationship between the SUA trajecteries and remission of NAFLD. The study enrolled employees who were attending their annual health examination. Furrherm...
Eligibility Criteria
Inclusion
- age \>=18 years;
- agree to be enrolled in this study.
Exclusion
- those taking antihypertensive or antidiabetic agents, lipid-lowing agents, or hypouricemic agents;
- those with alcohol consumption greater than 140 g/week for men and 70 g/week for women;
- those with a history of other known causes of chronic liver disease such as viral hepatitis or autoimmune hepatitis, and those using hepatotoxic medications.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT05245890
Start Date
March 1 2022
End Date
March 1 2024
Last Update
February 18 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.